Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.

Authors: Miller, Natalie J; Bhatia, Shailender; Parvathaneni, Upendra; Iyer, Jayasri G; Nghiem, Paul

Published In Curr Treat Options Oncol, (2013 Jun)

Abstract: Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer with a disease-specific mortality of approximately 40 %. The association of MCC with a recently discovered polyomavirus, combined with the increased incidence and mortality of MCC among immunocompromised patients, highlight the importance of the immune system in controlling this cancer. Initial management of MCC is summarized within the NCCN guidelines and in recently published reviews. The high rate of recurrent and metastatic disease progression in MCC, however, presents a major challenge in a cancer that lacks mechanism-based, disease-specific therapies. Traditional treatment approaches have focused on cytotoxic chemotherapy that, despite frequent initial efficacy, rarely provides durable responses and has high morbidity among the elderly. In addition, the immunosuppressive nature of chemotherapy is of concern when treating a virus-associated cancer for which survival is unusually tightly linked to immune function. With a median survival of 9.6 months after development of an initial metastasis (n = 179, described herein), and no FDA-approved agents for this cancer, there is an urgent need for more effective treatments. We review diverse management options for patients with advanced MCC, with a focus on emerging and mechanism-based therapies, some of which specifically target persistently expressed viral antigens. These treatments include single-dose radiation and novel immunotherapies, some of which are in clinical trials. Due to their encouraging efficacy, low toxicity, and lack of immune suppression, these therapies may offer viable alternatives to traditional cytotoxic chemotherapy.

PubMed ID: 23436166 Exiting the NIEHS site

MeSH Terms: Carcinoma, Merkel Cell/radiotherapy; Carcinoma, Merkel Cell/therapy*; Carcinoma, Merkel Cell/virology; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy/methods; Neoplasm Metastasis/radiotherapy; Neoplasm Metastasis/therapy; Neoplasm Recurrence, Local/mortality; Neoplasm Recurrence, Local/radiotherapy; Neoplasm Recurrence, Local/therapy; Polyomavirus Infections/complications; Polyomavirus Infections/therapy; Polyomavirus/drug effects; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms/radiotherapy; Skin Neoplasms/therapy*; Skin Neoplasms/virology; Tumor Virus Infections/complications; Tumor Virus Infections/therapy

to Top